Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04251130 · ClinicalTrials.gov registry record
Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRI
A clinical trial of Mild Cognitive Impairment, sponsored by University of Pennsylvania.
- Active
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT04251130 is a study of Mild Cognitive Impairment that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 150 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04251130, a study of Mild Cognitive Impairment, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will conduct a tau PET scan in cognitively normal older adults and patients with Mild Cognitive Impairment (MCI), enrolled in the National Alzheimer's Coordinating Center (NACC) study at the University of Pennsylvania's Penn Memory Center/Alzheimer's Disease Core Center (PMC/ADC).
Conditions Studied
Interventions
- DRUG 2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine
Study Locations (1)
Pennsylvania
- University of Pennsylvania, School of Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2020-03-11 |
| Est. Completion | 2027-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04251130
The ClinicalTrials.gov registry entry for NCT04251130 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (88% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 1 intervention - of which 2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine is the first listed.
NCT04251130 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04251130 about?
NCT04251130 is a clinical study titled "Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRI". The investigators will conduct a tau PET scan in cognitively normal older adults and patients with Mild Cognitive Impairment (MCI), enrolled in the National Alzheimer's Coordinating Center (NACC) study at the University of Pennsylvania's Penn Memory Center/Alzheimer's Disease Core Center (PMC/ADC).
What is the current status of trial NCT04251130?
This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2020-03-11. Estimated completion is 2027-01.
What conditions does trial NCT04251130 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment.
What interventions are being tested in trial NCT04251130?
The interventions under investigation include: 2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine (DRUG).
Who is sponsoring clinical trial NCT04251130?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04251130 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Wayfinding Intervention and Long-Term Memory
RECRUITING · NA
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
MCI Speech in Noise
RECRUITING
-
Dual Task Perturbation Training for OAwMCI
RECRUITING · NA
-
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
RECRUITING
-
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.